AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target with small molecule drugs. Depending on the progress of the research, Scorpion could receive up to $1.5 billion in option fees and milestone payments.
